AUTL - オ―トルス・セラピュ―ティクス (Autolus Therapeutics plc) オ―トルス・セラピュ―ティクス

 AUTLのチャート


 AUTLの企業情報

symbol AUTL
会社名 Autolus Therapeutics PLC (オ―トルス・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Autolus Therapeutics plc formerly Autolus Therapeutics Limited is a development-stage biopharmaceutical company. The company is engaged in developing programmed T-cell therapies for the treatment of cancer. The Company''s clinical-stage product candidates target hematological cancers. Its products candidates include AUTO2 AUTO3 AUTO4 and AUTO6. AUTO2 is a dual-targeting programmed T-cell therapy for the treatment of relapsed or refractory multiple myeloma targeting B-cell Maturation Antigen and the transmembrane activator. AUTO3 is a T-cell therapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma and pediatric relapsed acute B lymphocytic leukemia. Its AUTO4 is a T-cell therapy for the treatment of peripheral T-cell lymphoma.   オ―トルス・セラピュ―ティクスはイギリスのバイオ医薬品企業。主にがん治療に対する次世代のT細胞療法の開発に従事する。同社は独自のモジュ―ル型T細胞プログラミング技術を使用して、より正確にがん細胞を認識し、防御機能を破壊して、がん細胞を排除するより活性的なT細胞療法を開発する。本社所在地はロンドン。   Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.
本社所在地 Forest House 58 Wood Lane London W12 7RZ GBR
代表者氏名
代表者役職名
電話番号 +44 20-3829-6230
設立年月日 43132
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 126人
url www.autolus.com
nasdaq_url https://www.nasdaq.com/symbol/autl
adr_tso 10147059
EBITDA EBITDA(百万ドル) ー
終値(lastsale) 28.01
時価総額(marketcap) 284219122.59
時価総額 時価総額(百万ドル) 151.882
売上高 売上高(百万ドル) --
企業価値(EV) 企業価値(EV)(百万ドル) ー
当期純利益 当期純利益(百万ドル) --
決算概要 決算概要 BRIEF: For the fiscal year ended 30 September 2017 Autolus Therapeutics Ltd - ADR revenues increased 40% to $1.7M. Net loss increased 57% to $19.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 56% to $14.9M (expense) General and administrative - Balancing v increase of 86% to $7.1M (expense).

 AUTLのテクニカル分析


 AUTLのニュース

   Autolus Therapeutics PLC Sponsored ADR (AUTL) Upgraded to Strong Buy: What Does It Mean for the Stock?  2020/05/12 16:00:07 Zacks Investment Research
Autolus Therapeutics PLC Sponsored ADR (AUTL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
   Arix Bioscience Plc - Autolus announces pricing of public offering - Vox Markets  2020/01/23 07:00:00 VOX Markets
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014. LONDON, 23 January 2020: Arix Bioscience plc, a global venture capital company focused on investing in and building breakthrough biotech companies, today notes that its portfolio company Autolus Therapeutics plc, announced the pricing of its…
   Arix Bioscience Plc - Autolus announces new AUTO3 data at ASH - Vox Markets  2019/12/09 07:01:00 VOX Markets
Autolus announces new AUTO3 data at ASH. LONDON, 09 December 2019: Arix Bioscience plc, a global venture capital company focused on investing in and building breakthrough biotech companies, today notes that its portfolio company, Autolus Therapeutics plc, announced new data highlighting progress on its next-generation programmed T cell therapies to treat…
   Arix Bioscience Plc - Autolus to present new data at the ASH Annual Meeting - Vox Markets  2019/11/06 14:31:00 VOX Markets
Autolus to present new data at the ASH Annual Meeting. LONDON, 06 November 2019: Arix Bioscience plc, a global venture capital company focused on investing in and building breakthrough biotech companies, today notes that its portfolio company, Autolus Therapeutics Plc, has announced four oral and two poster presentations related to its AUTO1, AUTO2 and AUTO3…
   The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results  2019/08/13 11:25:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 12) GENMAB A/S/S ADR (NASDAQ: GMAB ) (IPOed July 1) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 13) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) Advaxis, Inc. (NASDAQ: ADXS ) AnaptysBio Inc (NASDAQ: ANAB ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Gamida Cell Ltd (NASDAQ: GMDA ) GENFIT S A/ADR (NASDAQ: GNFT ) Hemispherx BioPharma, Inc (NYSE: HEB ) Homology Medicines Inc (NASDAQ: FIXX ) INmune Bio Inc (NASDAQ: INMB )(reacted to second quarter results) Innovate Biopharmaceuticals Inc (NASDAQ: INNT ) Mallinckrodt PLC (NYSE: MNK )(was accused by Humana Inc (NYSE: HUM ) of manipulating prices of Achtar) Mersana Therapeutics Inc (NASDAQ: MRSN ) Novavax, Inc. (NASDAQ: NVAX )(reported new data from the Phase 3 trial dubbed PREPARE that evaluated its ResVax ) Obalon Therapeutics Inc (NASDAQ: OBLN ) Pfizer Inc. (NYSE: PFE ) Plus Therapeutics Inc (NASDAQ: PSTV ) Proteostasis …
   Arix Bioscience Plc - Autolus announces pricing of public offering - Vox Markets  2020/01/23 07:00:00 VOX Markets
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014. LONDON, 23 January 2020: Arix Bioscience plc, a global venture capital company focused on investing in and building breakthrough biotech companies, today notes that its portfolio company Autolus Therapeutics plc, announced the pricing of its…
   Arix Bioscience Plc - Autolus announces new AUTO3 data at ASH - Vox Markets  2019/12/09 07:01:00 VOX Markets
Autolus announces new AUTO3 data at ASH. LONDON, 09 December 2019: Arix Bioscience plc, a global venture capital company focused on investing in and building breakthrough biotech companies, today notes that its portfolio company, Autolus Therapeutics plc, announced new data highlighting progress on its next-generation programmed T cell therapies to treat…
   Arix Bioscience Plc - Autolus to present new data at the ASH Annual Meeting - Vox Markets  2019/11/06 14:31:00 VOX Markets
Autolus to present new data at the ASH Annual Meeting. LONDON, 06 November 2019: Arix Bioscience plc, a global venture capital company focused on investing in and building breakthrough biotech companies, today notes that its portfolio company, Autolus Therapeutics Plc, has announced four oral and two poster presentations related to its AUTO1, AUTO2 and AUTO3…
   The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results  2019/08/13 11:25:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 12) GENMAB A/S/S ADR (NASDAQ: GMAB ) (IPOed July 1) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 13) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) Advaxis, Inc. (NASDAQ: ADXS ) AnaptysBio Inc (NASDAQ: ANAB ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Gamida Cell Ltd (NASDAQ: GMDA ) GENFIT S A/ADR (NASDAQ: GNFT ) Hemispherx BioPharma, Inc (NYSE: HEB ) Homology Medicines Inc (NASDAQ: FIXX ) INmune Bio Inc (NASDAQ: INMB )(reacted to second quarter results) Innovate Biopharmaceuticals Inc (NASDAQ: INNT ) Mallinckrodt PLC (NYSE: MNK )(was accused by Humana Inc (NYSE: HUM ) of manipulating prices of Achtar) Mersana Therapeutics Inc (NASDAQ: MRSN ) Novavax, Inc. (NASDAQ: NVAX )(reported new data from the Phase 3 trial dubbed PREPARE that evaluated its ResVax ) Obalon Therapeutics Inc (NASDAQ: OBLN ) Pfizer Inc. (NYSE: PFE ) Plus Therapeutics Inc (NASDAQ: PSTV ) Proteostasis …
   The Daily Biotech Pulse: Obseva Gets The Greenlight, Verastem Climbs On Licensing Deal, Merit Medical Earnings Disappoint  2019/07/26 11:26:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 25) Akero Therapeutics Inc (NASDAQ: AKRO ) Anika Therapeutics Inc (NASDAQ: ANIK )( reported better-than-expected second-quarter results) Novocure Ltd (NASDAQ: NVCR )(reported strong second-quarter results) Repligen Corporation (NASDAQ: RGEN ) Xenetic Biosciences Inc (NASDAQ: XBIO ) Baxter International Inc (NYSE: BAX ) (reacted to strong second-quarter results) West Pharmaceutical Services Inc. (NYSE: WST ) (reacted to strong second-quarter results) Myovant Sciences Ltd (NYSE: MYOV ) Down In The Dumps (Biotech stocks hitting 52-week lows on July 25) Abeona Therapeutics Inc (NASDAQ: ABEO )(announced results from a Phase 1/2 trial of its ABO-102, its gene therapy candidate for San Filippo syndrome Type A) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP )(announced initiation of trial dubbed SPEARHEAD-1 that is evaluating ADP-A2M4 SPEAR T cells for patients with synovial sarcoma or myxoid/round cell liposarcoma) Aduro BioTech Inc (NASDAQ: ADRO ) Alkermes Plc (NASDAQ: ALKS )(reacted to Q2 results) Alterity Therapeutics Ltd (NASDAQ: ATHE ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aquestive Therapeutics Inc (NASDAQ: AQST ) Assembly Biosciences Inc (NASDAQ: ASMB ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) BENITEC BIOPHAR/S ADR (NASDAQ: BNTC ) ChemoCentryx Inc (NASDAQ: CCXI ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Foamix Pharmaceuticals Ltd (NASDAQ: FOMX ) Gamida Cell Ltd (NASDAQ: GMDA ) GENFIT S A/ADR (NASDAQ: GNFT ) Innoviva Inc (NASDAQ: INVA )(reported below-consensus second-quarter results) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA ) Neon Therapeutics Inc (NASDAQ: …
   Arix Bioscience Plc - Autolus announces new AUTO3 data at ASH - Vox Markets  2019/12/09 07:01:00 VOX Markets
Autolus announces new AUTO3 data at ASH. LONDON, 09 December 2019: Arix Bioscience plc, a global venture capital company focused on investing in and building breakthrough biotech companies, today notes that its portfolio company, Autolus Therapeutics plc, announced new data highlighting progress on its next-generation programmed T cell therapies to treat…
   Arix Bioscience Plc - Autolus to present new data at the ASH Annual Meeting - Vox Markets  2019/11/06 14:31:00 VOX Markets
Autolus to present new data at the ASH Annual Meeting. LONDON, 06 November 2019: Arix Bioscience plc, a global venture capital company focused on investing in and building breakthrough biotech companies, today notes that its portfolio company, Autolus Therapeutics Plc, has announced four oral and two poster presentations related to its AUTO1, AUTO2 and AUTO3…
   The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results  2019/08/13 11:25:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 12) GENMAB A/S/S ADR (NASDAQ: GMAB ) (IPOed July 1) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 13) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) Advaxis, Inc. (NASDAQ: ADXS ) AnaptysBio Inc (NASDAQ: ANAB ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Gamida Cell Ltd (NASDAQ: GMDA ) GENFIT S A/ADR (NASDAQ: GNFT ) Hemispherx BioPharma, Inc (NYSE: HEB ) Homology Medicines Inc (NASDAQ: FIXX ) INmune Bio Inc (NASDAQ: INMB )(reacted to second quarter results) Innovate Biopharmaceuticals Inc (NASDAQ: INNT ) Mallinckrodt PLC (NYSE: MNK )(was accused by Humana Inc (NYSE: HUM ) of manipulating prices of Achtar) Mersana Therapeutics Inc (NASDAQ: MRSN ) Novavax, Inc. (NASDAQ: NVAX )(reported new data from the Phase 3 trial dubbed PREPARE that evaluated its ResVax ) Obalon Therapeutics Inc (NASDAQ: OBLN ) Pfizer Inc. (NYSE: PFE ) Plus Therapeutics Inc (NASDAQ: PSTV ) Proteostasis …
   The Daily Biotech Pulse: Obseva Gets The Greenlight, Verastem Climbs On Licensing Deal, Merit Medical Earnings Disappoint  2019/07/26 11:26:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 25) Akero Therapeutics Inc (NASDAQ: AKRO ) Anika Therapeutics Inc (NASDAQ: ANIK )( reported better-than-expected second-quarter results) Novocure Ltd (NASDAQ: NVCR )(reported strong second-quarter results) Repligen Corporation (NASDAQ: RGEN ) Xenetic Biosciences Inc (NASDAQ: XBIO ) Baxter International Inc (NYSE: BAX ) (reacted to strong second-quarter results) West Pharmaceutical Services Inc. (NYSE: WST ) (reacted to strong second-quarter results) Myovant Sciences Ltd (NYSE: MYOV ) Down In The Dumps (Biotech stocks hitting 52-week lows on July 25) Abeona Therapeutics Inc (NASDAQ: ABEO )(announced results from a Phase 1/2 trial of its ABO-102, its gene therapy candidate for San Filippo syndrome Type A) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP )(announced initiation of trial dubbed SPEARHEAD-1 that is evaluating ADP-A2M4 SPEAR T cells for patients with synovial sarcoma or myxoid/round cell liposarcoma) Aduro BioTech Inc (NASDAQ: ADRO ) Alkermes Plc (NASDAQ: ALKS )(reacted to Q2 results) Alterity Therapeutics Ltd (NASDAQ: ATHE ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aquestive Therapeutics Inc (NASDAQ: AQST ) Assembly Biosciences Inc (NASDAQ: ASMB ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) BENITEC BIOPHAR/S ADR (NASDAQ: BNTC ) ChemoCentryx Inc (NASDAQ: CCXI ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Foamix Pharmaceuticals Ltd (NASDAQ: FOMX ) Gamida Cell Ltd (NASDAQ: GMDA ) GENFIT S A/ADR (NASDAQ: GNFT ) Innoviva Inc (NASDAQ: INVA )(reported below-consensus second-quarter results) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA ) Neon Therapeutics Inc (NASDAQ: …
   The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug  2019/07/25 11:21:54 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 24) Acasti Pharma Inc (NASDAQ: ACST ) Cardiovascular Systems Inc (NASDAQ: CSII ) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Masimo Corporation (NASDAQ: MASI ) VolitionRX Ltd (NYSE: VNRX ) Edwards Lifesciences Corp (NYSE: EW )(reported a beat-and-raise second quarter) Haemonetics Corporation (NYSE: HAE ) Down In The Dumps (Biotech stocks hitting 52-week lows on July 24) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Foamix Pharmaceuticals Ltd (NASDAQ: FOMX ) GENFIT S A/ADR (NASDAQ: GNFT ) ContraVir Pharmaceuticals Inc (NASDAQ: HEPA) Innoviva Inc (NASDAQ: INVA ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) Neovasc Inc (NASDAQ: NVCN ) Organogenesis Holdings Inc (NASDAQ: ORGO ) Pluristem Therapeutics Inc. (NASDAQ: PSTI )(announced 1-for-10 reverse stock split) Regulus Therapeutics Inc (NASDAQ: RGLS )(FDA imposed partial clinical hold on its kidney disease drug) Surface Oncology Inc (NASDAQ: SURF ) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) Wave Life Sciences Ltd (NASDAQ: WVE ) Stocks In Focus FDA Approves Lilly's Nasally-Administered Low Blood Sugar Drug Eli Lilly And Co (NYSE: LLY ) said the FDA has approved its Baqsimi, the first and only nasally administered glucagon to treat severe hypoglycemia in a single, fixed, 3mg dose.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 オ―トルス・セラピュ―ティクス AUTL Autolus Therapeutics plc)

 twitter  (公式ツイッターやCEOツイッターなど)